RU2006131597A - Ингибиторы dпп-iv - Google Patents
Ингибиторы dпп-iv Download PDFInfo
- Publication number
- RU2006131597A RU2006131597A RU2006131597/04A RU2006131597A RU2006131597A RU 2006131597 A RU2006131597 A RU 2006131597A RU 2006131597/04 A RU2006131597/04 A RU 2006131597/04A RU 2006131597 A RU2006131597 A RU 2006131597A RU 2006131597 A RU2006131597 A RU 2006131597A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- group
- independently selected
- compound according
- halogen
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 6
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 title claims 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 title claims 3
- 125000000217 alkyl group Chemical group 0.000 claims abstract 179
- 150000001875 compounds Chemical class 0.000 claims abstract 40
- 229910052736 halogen Inorganic materials 0.000 claims abstract 33
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 21
- 150000002367 halogens Chemical group 0.000 claims abstract 20
- 238000006467 substitution reaction Methods 0.000 claims abstract 20
- 229910052799 carbon Inorganic materials 0.000 claims abstract 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 11
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 10
- 125000004043 oxo group Chemical group O=* 0.000 claims abstract 8
- 150000003839 salts Chemical class 0.000 claims abstract 8
- 229920006395 saturated elastomer Polymers 0.000 claims abstract 8
- 125000001624 naphthyl group Chemical group 0.000 claims abstract 6
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims abstract 5
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 claims abstract 5
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims abstract 5
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims abstract 5
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims abstract 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract 2
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 2
- 239000001301 oxygen Substances 0.000 claims abstract 2
- 125000005843 halogen group Chemical group 0.000 claims 13
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 8
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 8
- -1 heterobicycle Chemical group 0.000 claims 7
- 239000000556 agonist Substances 0.000 claims 5
- 102000004877 Insulin Human genes 0.000 claims 4
- 108090001061 Insulin Proteins 0.000 claims 4
- 229940125396 insulin Drugs 0.000 claims 4
- 108010088406 Glucagon-Like Peptides Proteins 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 206010056438 Growth hormone deficiency Diseases 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
- 102100029077 3-hydroxy-3-methylglutaryl-coenzyme A reductase Human genes 0.000 claims 1
- 101710158485 3-hydroxy-3-methylglutaryl-coenzyme A reductase Proteins 0.000 claims 1
- MVQVNTPHUGQQHK-UHFFFAOYSA-N 3-pyridinemethanol Chemical compound OCC1=CC=CN=C1 MVQVNTPHUGQQHK-UHFFFAOYSA-N 0.000 claims 1
- 208000004611 Abdominal Obesity Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- 206010065941 Central obesity Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 229940122904 Glucagon receptor antagonist Drugs 0.000 claims 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 102000023984 PPAR alpha Human genes 0.000 claims 1
- 108010028924 PPAR alpha Proteins 0.000 claims 1
- 102000000536 PPAR gamma Human genes 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 101150014691 PPARA gene Proteins 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 102000014743 Pituitary Adenylate Cyclase-Activating Polypeptide Receptors Human genes 0.000 claims 1
- 108010064032 Pituitary Adenylate Cyclase-Activating Polypeptide Receptors Proteins 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000002404 acyltransferase inhibitor Substances 0.000 claims 1
- 108060000200 adenylate cyclase Proteins 0.000 claims 1
- 102000030621 adenylate cyclase Human genes 0.000 claims 1
- 239000002269 analeptic agent Substances 0.000 claims 1
- 229940124599 anti-inflammatory drug Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 150000004283 biguanides Chemical class 0.000 claims 1
- 108091022863 bile acid binding Proteins 0.000 claims 1
- 102000030904 bile acid binding Human genes 0.000 claims 1
- 230000001906 cholesterol absorption Effects 0.000 claims 1
- 239000005515 coenzyme Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 201000010066 hyperandrogenism Diseases 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000003914 insulin secretion Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000037356 lipid metabolism Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000004235 neutropenia Diseases 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 229960004738 nicotinyl alcohol Drugs 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 230000001817 pituitary effect Effects 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 239000003352 sequestering agent Substances 0.000 claims 1
- 230000019100 sperm motility Effects 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- VOVDQQQGYGFYKU-JTQLQIEISA-N CC(C[C@@H](Cc(cccc1)c1F)N)=O Chemical compound CC(C[C@@H](Cc(cccc1)c1F)N)=O VOVDQQQGYGFYKU-JTQLQIEISA-N 0.000 description 1
- ABRGFZIXRKAUJS-UHFFFAOYSA-N CCN(C)Cc1ccccc1 Chemical compound CCN(C)Cc1ccccc1 ABRGFZIXRKAUJS-UHFFFAOYSA-N 0.000 description 1
- QUVTTYBFMDDFBM-UHFFFAOYSA-N CCNCCc(cc1)ccc1Cl Chemical compound CCNCCc(cc1)ccc1Cl QUVTTYBFMDDFBM-UHFFFAOYSA-N 0.000 description 1
- XSGSTHQZHRLSHO-UHFFFAOYSA-N CCNCCc(cc1)ccc1OC Chemical compound CCNCCc(cc1)ccc1OC XSGSTHQZHRLSHO-UHFFFAOYSA-N 0.000 description 1
- AJKNGHMCGVJIPW-UHFFFAOYSA-N CCNCCc(cc1)ccc1S(N)(=O)=O Chemical compound CCNCCc(cc1)ccc1S(N)(=O)=O AJKNGHMCGVJIPW-UHFFFAOYSA-N 0.000 description 1
- HDNRAPAFJLXKBV-UHFFFAOYSA-N CCc(cc1)ccc1OC Chemical compound CCc(cc1)ccc1OC HDNRAPAFJLXKBV-UHFFFAOYSA-N 0.000 description 1
- WEBZMGHVGASLFJ-UHFFFAOYSA-N CCc1ccccc1SC Chemical compound CCc1ccccc1SC WEBZMGHVGASLFJ-UHFFFAOYSA-N 0.000 description 1
- OOTKJPZEEVPWCR-UHFFFAOYSA-N CNCc1ccccn1 Chemical compound CNCc1ccccn1 OOTKJPZEEVPWCR-UHFFFAOYSA-N 0.000 description 1
- RCSSHZGQHHEHPZ-QMMMGPOBSA-N C[C@@H](c1ccccc1)NC Chemical compound C[C@@H](c1ccccc1)NC RCSSHZGQHHEHPZ-QMMMGPOBSA-N 0.000 description 1
- XPEQDUBKWGJLRZ-UHFFFAOYSA-N Cc1ccccc1C(CN1CCCC1)N Chemical compound Cc1ccccc1C(CN1CCCC1)N XPEQDUBKWGJLRZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/31—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms
- C07C311/35—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atoms of the sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C07C323/41—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/18—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/76—Benzo[c]pyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
- Immunology (AREA)
Abstract
1. Соединение формулы (I)Z-C(RR)-C(RNH)-C(RR)-X-N(RR)или его фармацевтически приемлемая соль, отличающееся тем, чтоZ выбран из группы, состоящей из фенила; нафтила; инденила; Сциклоалкила; инданила, тетралинила, декалинила, гетероцикла и гетеробицикла, где Z факультативно несет замещение одним или более R, где Rнезависимо выбран из группы, состоящей из галогена; CN; ОН; NH; оксо-группы (=O), причем кольцо является по меньшей мере частично насыщенным; Rи R;Rвыбран из группы, состоящей из Салкила; O-Cалкила и S-Cалкила, где углеродная цепь Rфакультативно содержит кислород и где Rфакультативно несет замещение одним или более галогеном, независимо выбранным из группы, состоящей из F и Cl;Rвыбран из группы, состоящей из фенила, гетероцикла и Сциклоалкила, где Rфакультативно несет замещение одним или более R, где Rнезависимо выбраны из группы, состоящей из галогена; CN; ОН; NH; оксо-группы (=O), причем кольцо является по меньшей мере частично насыщенным; Cалкила; O-Cалкила и S-Салкила;R, Rнезависимо выбраны из группы, состоящей из Н, F, ОН и R;R, Rнезависимо выбраны из группы, состоящей из Н, F и R;Rнезависимо выбран из группы, состоящей из Салкила и O-Cалкила, причем Rфакультативно несет замещение одним или более галогеном, независимо выбранным из группы, состоящей из F и Cl;Rпредставляет собой Салкил, где Rфакультативно несет замещение одним или более галогеном, независимо выбранным из группы, состоящей из F и Cl;Rвыбран из группы, состоящей из Н и Салкила;факультативно одна или большее число пар, составленных из R, R, R, Rи R, независимо выбранных из группы, состоящей из пар R/R; R/R; R/Rи R/R, образуют Сциклоалкильное кольцо, которое факультативно несет замещение одним или более R, где R
Claims (36)
1. Соединение формулы (I)
Z-C(R1R2)-C(R3NH2)-C(R4R5)-X-N(R6R7)
или его фармацевтически приемлемая соль, отличающееся тем, что
Z выбран из группы, состоящей из фенила; нафтила; инденила; С3-7циклоалкила; инданила, тетралинила, декалинила, гетероцикла и гетеробицикла, где Z факультативно несет замещение одним или более R8, где R8 независимо выбран из группы, состоящей из галогена; CN; ОН; NH2; оксо-группы (=O), причем кольцо является по меньшей мере частично насыщенным; R9 и R10;
R9 выбран из группы, состоящей из С1-6алкила; O-C1-6алкила и S-C1-6алкила, где углеродная цепь R9 факультативно содержит кислород и где R9 факультативно несет замещение одним или более галогеном, независимо выбранным из группы, состоящей из F и Cl;
R10 выбран из группы, состоящей из фенила, гетероцикла и С3-7циклоалкила, где R10 факультативно несет замещение одним или более R11, где R11 независимо выбраны из группы, состоящей из галогена; CN; ОН; NH2; оксо-группы (=O), причем кольцо является по меньшей мере частично насыщенным; C1-6алкила; O-C1-6алкила и S-С1-6алкила;
R1, R4 независимо выбраны из группы, состоящей из Н, F, ОН и R4a;
R2, R5 независимо выбраны из группы, состоящей из Н, F и R4b;
R4a независимо выбран из группы, состоящей из С1-6алкила и O-C1-6алкила, причем R4a факультативно несет замещение одним или более галогеном, независимо выбранным из группы, состоящей из F и Cl;
R4b представляет собой С1-6алкил, где R4b факультативно несет замещение одним или более галогеном, независимо выбранным из группы, состоящей из F и Cl;
R3 выбран из группы, состоящей из Н и С1-6алкила;
факультативно одна или большее число пар, составленных из R1, R2, R3, R4 и R5, независимо выбранных из группы, состоящей из пар R1/R2; R2/R3; R3/R4 и R4/R5, образуют С3-7циклоалкильное кольцо, которое факультативно несет замещение одним или более R12, где R12 независимо выбран из группы, состоящей из F; Cl и ОН;
Х выбран из группы, состоящей из S(O), S(O)2, C(O) и C(R13R14);
R13, R14 независимо выбраны из группы, состоящей из Н; F; C1-6алкила; R15 и R16;
Факультативно, одна или более пар, составленных из R5, R13 и R14, выбранных из группы, состоящей из R5/R13 и R13/R14, образуют С3-7циклоалкильное кольцо, которое факультативно несет замещение одним или более R17, где R17 независимо выбран из группы, состоящей из F, Cl и ОН;
R15 выбран из группы, состоящей из фенила; нафтила и инденила, причем R15 факультативно несет замещение одним или более R18, где R18 независимо выбран из группы, состоящей из R19, R20, галогена, CN, СООН, ОН, С(O)NH2, S(O)2NH2, S(O)NH2, C1-6алкила, O-C1-6алкила, S-C1-6алкила, COO-C1-6алкила, OC(O)-C1-6алкила, C(O)N(R21)-C1-6алкила, S(O)2N(R21)-С1-6алкила, S(O)N(R21)-C1-6алкила, S(O)2-С1-6алкила, S(O)-С1-6алкила, N(R21)S(O)2-C1-6алкила и N(R21)S(O)-C1-6алкила, где каждый C1-6алкил факультативно несет замещение одним или более галогеном, независимо выбранным из группы, состоящей из F и Cl;
R16 выбран из группы, состоящей из гетероцикла, гетеробицикла, С3-7циклоалкила, инданила, тетралинила и декалинила, где R16 факультативно несет замещение одним или более R22, где R22 независимо выбран из группы, состоящей из R19; R20; галогена; CN; ОН; оксо-группы (=O), причем кольцо является по меньшей мере частично насыщенным; NH2; СООН, С(O)NH2, S(O)2NH2, S(O)NH2, C1-6алкила, O-C1-6алкила, S-C1-6алкила, N(R23)-C1-6алкила, COO-C1-6алкила, OC(O)-C1-6алкила, C(O)N(R23)-C1-6алкила, N(R23)-C(O)-C1-6алкила, S(O)2N(R23)-C1-6алкила, S(O)N(R23)-C1-6алкила, S(O)2-C1-6алкила, S(O)-C1-6алкила, N(R23)S(O)2-C1-6алкила и N(R23)S(O)-C1-6алкила, где каждый C1-6алкил факультативно несет замещение одним или более галогеном, независимо выбранным из группы, состоящей из F и Cl;
R19 выбран из группы, состоящей из фенила и нафтила, где R19 факультативно несет замещение одним или более R24, где R24 независимо выбран из группы, состоящей из галогена, CN, СООН, ОН, С(O)NH2, S(O)2NH2, S(O)NH2, С1-6алкила, О-С1-6алкила, S-C1-6алкила, СОО-С1-6алкила, ОС(O)-С1-6алкила, С(O)N(R25)-С1-6алкила, S(O)2N(R25)-C1-6алкила, S(O)N(R25)-C1-6алкила, S(O)2-С1-6алкила, S(O)-С1-6алкила, N(R25)S(O)2-C1-6алкила и N(R25)S(O)-С1-6алкила, где каждый C1-6алкилфакультативно несет замещение одним или более галогеном, независимо выбранным из группы, состоящей из F и Cl;
R20 выбран из группы, состоящей из гетероцикла, гетеробицикла и С3-7циклоалкила, где R20 факультативно несет замещение одним или более R26, где R26 независимо выбран из группы, состоящей из галогена; CN; ОН; оксо-группы (=O), причем кольцо является по меньшей мере частично насыщенным; NH2, СООН, C(O)NH2, S(O)2NH2, S(O)NH2, C1-6алкила, O-C1-6алкила, S-C1-6алкила, N(R27)-C1-6алкила, COO-C1-6алкила, OC(O)-C1-6 алкила, C(O)N(R27)-C1-6алкила, N(R27)-С(O)-С1-6алкила, S(O)2N(R27)-C1-6алкила, S(O)N(R27)-C1-6алкила, S(O)2-C1-6алкила, S(O)-C1-6алкила, N(R27)S(O)2-C1-6алкила и N(R27)S(O)-C1-6алкила, где каждый C1-6алкил факультативно несет замещение одним или более галогеном, независимо выбранным из группы, состоящей из F и Cl;
R21, R23, R25, R27 независимо выбраны из группы, состоящей из Н и C1-6алкила, который факультативно несет замещение одним или более R28, где R28 независимо выбран из группы, состоящей из F, Cl и ОН;
R6, R7 независимо выбраны из группы, состоящей из Н, (C(R29R30))m-X1-Z1 и (C(R31R32))n-X2X3Z2, при условии, что R6, R7 выбирают таким образом, чтобы R6 и R7 не были одновременно выбраны из группы, состоящей из Н, СН3, СН2СН3, СН2СН2СН3 и СН(СН3)2
Факультативно R6 и R7 независимо представляют собой C1-4алкил, который несет замещение одним или более R29a, где R29a независимо выбран из группы, состоящей из R29b и Z1, при условии, что R6 и R7 выбирают таким образом, чтобы R6 и R7 не были одновременно независимо выбраны из группы, состоящей из СН3; СН2СН3; СН2СН2СН3; and СН(СН3)2;
R29, R29b, R30, R31, R32 независимо выбраны из группы, состоящей из Н, галогена, CN, ОН, NH2, СООН, С(O)NH2, S(O)2NH2, S(O)NH2, C1-6алкила, O-C1-6алкила, N(R32a)-С1-6алкила, COO-C1-6алкила, OC(O)-C1-6алкила, C(O)N(R32a)-C1-6алкила, N(R32a)-C(O)-C1-6алкила, S(O)2N(R32a)-C1-6алкила, S(O)N(R32a)C1-6алкила, S(O)2-C1-6алкила, S(O)-C1-6алкила, N(R32a)S(O)2-C1-6алкила и N(R32a)S(O)-C1-6алкила, где каждый C1-6алкил факультативно несет замещение одним или более галогеном, независимо выбранным из группы, состоящей F и Cl;
R32a выбран из группы, состоящей из Н и C1-6алкила, который факультативно несет замещение одним или более галогеном, независимо выбранным из группы, состоящей из F и Cl;
Факультативно, одна или большее число пар, составленных из R29, R30, R31, R32, независимо выбранных из R29/R30 и R31/R32, образуют С3-7циклоалкильное кольцо, которое факультативно несет замещение одним или более R32b, где R32b независимо выбран из группы, состоящей из F; Cl и ОН;
m равно 0, 1, 2, 3 или 4;
n равно 2, 3 или 4;
X1 независимо выбран из группы, состоящей из ковалентной связи, -C1-6алкила, -C1-6алкил-O-, -C1-6алкил-N(R33)-, -С(O)-, -C(O)-C1-6алкила, -C(O)-C1-6алкил-O-, -C(O)-C1-6алкил-N(R33)-, -С(O)O-, -C(O)O-C1-6алкила, -C(O)O-C1-6алкил-O-, -C(O)O-C1-6алкил-N(R33)-, -C(O)N(R33)-, -C(O)N(R33)-C1-6алкила, -C(О)N(R33)-C1-6алкил-O-, -С(O)N(R33)-C1-6алкил-N(R34)-, -S(O)2-, -S(O)-, -S(O)2-C1-6алкила, -S(O)-C1-6алкила, -S(O)2-C1-6алкил-O-, -S(O)-C1-6алкил-O-, -S(O)2-C1-6алкил-N(R33)- и -S(O)-C1-6алкил-N(R33)-, где каждый C1-6алкил факультативно несет замещение одним или более галогеном, независимо выбранным независимо из группы, состоящей из F и Cl;
X2 выбран из группы, состоящей из -O-, -S-, -S(O)-, S(O)2- и -N(R35)-;
X3 выбран из группы, состоящей из ковалентной связи, -С1-6алкила, -C1-6алкил-O-; -C1-6алкил-N(R36)-, -С(O)-, -C(O)-C1-6алкила, -С(O)-С1-6алкил-O-, -С(O)-С1-6алкил-N(R36)-, -С(O)O-, -С(O)O-С1-6алкила, -С(O)O-С1-6алкил-O-, -C(O)O-C1-6алкил-N(R36)-, -C(O)N(R36)-, -C(O)N(R36)-C1-6алкила, -C(O)N(R36)-C1-6алкил-O- и -C(O)N(R36)-C1-6алкил-N(R37)-, где каждый C1-6алкил факультативно несет замещение одним или более галогеном, независимо выбранным из группы, состоящей из F и Cl;
Х2-Х3 могут быть независимо выбраны из группы, состоящей из -N(R35)-S(O)2, -N(R35)S(O)-, -N(R35)-S(О)2-С1-6алкила, -N(R35)-S(O)2-C1-6алкила, -N(R35)-S(O)2-C1-6алкил-О-, -N(R35)-S(O)2-C1-6алкил-О-, -N(R35)-S(O)2-C1-6алкил-N(R36)-, и -N(R35)-S(O)-С1-6алкил-N(R36)-, где каждый C1-6алкил факультативно несет замещение одним или более галогеном, независимо выбранным из группы, состоящей из F и Cl;
R33, R34, R35, R36, R37 независимо выбраны из группы, состоящей из Н и С1-6алкила, который факультативно несет замещение одним или более галогеном, независимо выбранным из группы, состоящей из F и Cl;
Z1, Z2 независимо выбраны из группы, состоящей из Z3 и -C(R37a)Z3aZ3b;
R37a выбран из группы, состоящей из Н, и С1-6алкила, который факультативно несет замещение одним или более атомов F;
Z3, Z3a, Z3b независимо выбраны из группы, состоящей из Н, Т1, Т2, C1-6алкила, C1-6алкил-Т1 и C1-6алкил-Т2, где каждый C1-6алкил факультативно несет замещение одним или более R37b, причем R37b независимо выбран из группы, состоящей из галогена, CN, ОН, NH2, COOH, C(O)NH2, S(O)2NH2, S(O)NH2, С1-6алкила, O-C1-6алкила, N(R37c)-C1-6алкила, COO-C1-6алкила, OC(O)-C1-6алкила, C(O)N(R37c)-C1-6алкила, N(R37c)-C(O)-C1-6алкила, S(O)2N(R37c)-C1-6алкила, S(O)N(R37c)-C1-6алкила, S(O)2-С1-6алкила, S(O)-С1-6алкила, N(R37c)S(O)2-C1-6алкила и N(R37c)S(O)-C1-6алкила, где каждый С1-6алкил факультативно несет замещение одним или более галогеном, независимо выбранным из группы, состоящей из F и Cl;
Т1 выбран из группы, состоящей из фенила; нафитила и инденила; где Т1 факультативно несет замещение одним или более R38; причем R38 независимо выбран из группы, состоящей из галогена, CN, R39, COOH, ОН, C(O)NH2, S(O)2NH2, S(O)NH2, COOT3, ОТ3, ST3, C(O)N(R40)T3, S(O)2N(R40)T3, S(O)N(R40)T3 и Т3,
Т2 выбран из группы, состоящей из С3-7циклоалкила, инданила, тетралинила, декалинила, гетероцикла и гетеробицикла, причем Т2 факультативно несет замещение одним или более R41, где R41 независимо выбран из группы, состоящей из галогена; CN; R42; ОН; оксо-группы (=O), причем кольцо является по меньшей мере частично насыщенным; NH2; COOH, C(O)NH2, S(O)2NH2, S(O)NH2, COOT3, ОТ3, C(O)N(R43)T3, S(O)2N(R43)T3, S(O)N(R43)T3, N(R43)T3 и Т3;
R39 выбран из группы, состоящей из C1-6алкила, O-C1-6алкила, S-C1-6алкила, COO-C1-6алкила, ОС(O)-C1-6алкила, C(O)N(R44)-C1-6алкила, S(O)2N(R44)-С1-6алкила, S(O)N(R44)-C1-6алкила, S(O)-С1-6алкила, S(O)2-С1-6алкила, N(R44)S(O)2-C1-6алкила и N(R44)S(O)-C1-6алкила, где каждый C1-6алкил факультативно несет замещение одним или более R45, где R45 независимо выбран из группы, состоящей из F, COOR46, C(O)N(R46R47), S(O)2N(R46R47), OR46, N(R46R47), Т3, O-Т3, и N(R46)-T3;
R42 выбран из группы, состоящей из С1-6алкила, O-C1-6алкила, S-C1-6алкила, N(R48)-C1-6алкила, COO-C1-6алкила, ОС(O)-С1-6алкила, C(O)N(R48)- C1-6алкила, N(R48)-C(O)-C1-6алкила, S(O)2N(R48)-C1-6алкила, S(O)N(R48)-C1-6алкила, S(O)-C1-6алкила, S(O)2-C1-6алкила, -N(R48)S(O)2-C1-6алкила и -N(R48)S(O)-C1-6алкила, где каждый C1-6алкил факультативно несет замещение одним или более R45, где R45 независимо выбран из группы, состоящей из F, COOR49, C(O)N(R49R50), S(O)2N(R49R50), S(O)N(R49R50), OR49, N(R49R50), Т3, O-Т3 и N(R49)-T3;
R40, R43, R44, R46, R47, R48, R49, R50 независимо выбраны из группы, состоящей из Н и C1-6алкила;
Т3 выбран из группы, состоящей из Т4 и Т5;
Т4 выбран из группы, состоящей из фенила, нафтила и инденила, где Т4 факультативно несет замещение одним или более R51, где R51 независимо выбран из группы, состоящей из галогена, CN, COOR52, OR52, C(O)N(R52R53), S(O)2N(R52R53), C1-6алкила, О-С1-6алкила, S-С1-6алкила, СОО-С1-6алкила, OC(O)-C1-6алкила, С(O)N(R52)-С1-6алкила, S(O)2N(R52)-С1-6алкила, S(O)N(R52)-C1-6алкила, S(O)2-С1-6алкила, S(O)-С1-6алкила, N(R52)S(O)2-С1-6алкила, и N(R52)S(O)-C1-6алкила, где каждый С1-6алкил факультативно несет замещение одним или более галогеном, независимо выбранным из группы, состоящей из F и Cl;
Т5 выбран из группы, состоящей из гетероцикла, гетеробицикла, С3-7циклоалкила, инданила, тетералинила и декалинила, где Т5 факультативно несет замещение одним или более R54, где R54 независимо выбран из группы, состоящей из галогена; CN; OR55; оксо-группы (=O), причем кольцо является по меньшей мере частично насыщенным; N(R55R56); COOR55, C(O)N(R55R56), S(O)2N(R55R56), S(O)N(R55R56), C1-6алкила, O-C1-6алкила, S-C1-6алкила, N(R55)-C1-6алкила, COO-C1-6алкила, ОС(O)-С1-6алкила, C(O)N(R55)-C1-6алкила, N(R55)-C(O)-C1-6алкила, S(O)2N(R55)-C1-6алкила, S(O)N(R55)-С1-6алкила, S(O)2-С1-6алкила, S(O)-С1-6алкила, N(R55)S(O)2-C1-6алкила и N(R55)S(O)-С1-6алкила, где каждый C1-6алкил факультативно несет замещение или более галогеном, независимо выбранным из группы, состоящей из F и Cl;
R52, R53, R55, R56, независимо выбраны из группы, состоящей из Н и C1-6алкила.
3. Соединение по п.1, отличающееся тем, что Z представляет собой фенил или гетероцикл.
4. Соединение по п.1, отличающееся тем, что Z факультативно несет замещение 1 или 2 R8, которые могут быть одинаковыми или разными.
5. Соединение по п.1, отличающееся тем, что R8 выбран из группы, состоящей из Cl, F, CN, СН3 и ОСН3.
6. Соединение по п.1, отличающееся тем, что Z представляет собой 2-фторфенил.
7. Соединение по п.1, отличающееся тем, что R1, R4 независимо выбраны из группы, состоящей из Н, F, ОН, СН3 и ОСН3.
8. Соединение по п.1, отличающееся тем, что R2, R5 независимо выбраны из группы, состоящей из Н, F и СН3.
9. Соединение по п.1, отличающееся тем, что R1, R2, R4 и R5 представляют собой Н.
10. Соединение по п.1, отличающееся тем, что R3 представляет собой Н.
11. Соединение по п.1, отличающееся тем, что Х представляет собой С(O) или S(O)2.
12. Соединение по п.1, отличающееся тем, что R6 выбран из группы, состоящей из Н и СН3.
13. Соединение по п.1, отличающееся тем, что X1 представляет собой ковалентную связь.
14. Соединение по п.1, отличающееся тем, что m=0, 1, 2 или 3.
15. Соединение по п.1, отличающееся тем, что R7 представляет собой Z1.
16. Соединение по п.1, отличающееся тем, что R7 представляет собой C1-4алкил, замещенный 1-4 R29a, которые могут быть одинаковыми или разными.
17. Соединение по п.16, отличающееся тем, что R7 выбран из группы, состоящей из CH-(R29a)2, CHR29a-CH2R29a, CH2-CH(R29a)2, CH2-CHR29a-CH2R29a и CH2-CH2-CH(R29a)2.
18. Соединение по п.1, отличающееся тем, что R29a выбран из группы, состоящей из R29b и Z1, и где R29b выбран из группы, состоящей из Н, F, Cl, NH2, NHCH3, N(CH3)2, СН3 и C2H5.
19. Соединение по п.1, отличающееся тем, что R29a выбран из группы, состоящей из R29b и Z1;, и где Z1 выбран из группы, состоящей из Т1 и Т2.
20. Соединение по п.1, отличающееся тем, что Т1 представляет собой фенил, и где Т1 факультативно несет замещение одним-тремя R38, которые могут быть одинаковыми или разными.
21. Соединение по п.1, отличающееся тем, что R38 независимо выбран из группы, состоящей из F, Cl, CN, СН3, C2H5, CH2CH2CH3, СН(СН3)2, CF3, O-СН3, O-C2H5. S-СН3, SO2NH2, Т3 и O-Т3.
23. Соединение по п.1, отличающееся тем, что R41 выбран из группы, состоящей из ОН, СН3 и Т3;
24. Соединение по п.1, отличающееся тем, что Т3 представляет собой Т4.
25. Соединение по п.1, отличающееся тем, что Т4 представляет собой фенил, где Т4 факультативно несет замещение одним-тремя R51, которые могут быть одинаковыми или разными.
26 Соединение по п.1, отличающееся тем, что R51 независимо выбран из группы, состоящей из F, Cl, СН3, С2Н5, СН2СН2СН3, СН(СН3)2, CF3, O-СН3, O-С2Н5, S-СН3 и SO2NH2.
27. Соединение по п.1, отличающееся тем, что Т3 представляет собой Т5.
28. Соединение по п.1, отличающееся тем, что Т5 представляет собой гетероцикл, где Т5 факультативно несет замещение одним или двумя R54, которые могут быть одинаковыми или разными.
29. Соединение по п.1, отличающееся тем, что R54 выбран из группы, состоящей из ОН и СН3.
30. Соединение по п.1, выбранное из группы, состоящей из
31. Соединение, которое представляет собой пролекарство соединений согласно настоящему изобретению по п.1.
32. Фармацевтическая композиция, содержащая соединение по любому из пп 1-31 или его фармацевтически приемлемую соль совместно с фармацевтически приемлемым носителем.
33. Фармацевтическая композиция по п.32, содержащая одно или более дополнительных соединений или их фармацевтически приемлемых солей, выбранных из группы, состоящей из другого соединения по любому из пп.1-27; другого ингибитора ДПП-IV; сенсибилизаторов к инсулину; агонистов РАПП; бигуанидов; ингибиторов протеин тирозинфосфатазы-1В (РТР-1В); инсулина и миметиков инсулина; производных сульфонилмочевины и других веществ, стимулирующих секрецию инсулина, ингибиторов a-глюкозидазы, антагонистов рецепторов к глюкагону, глюкагоноподобного пептида (GLP-1), миметиков GLP-1 и агонистов рецепторов к GLP-1, гастроингибиторного пептида (ГИП), миметиков ГИП и агонистов рецепторов к ГИП; пептида, активирующго аденилатциклазу гипофиза (РАСАР), миметиков РАСАР и агонистов рецептора 3 к РАСАР; препаратов, снижающих содержание холестерина, ингибиторов HMG-CoA редуктазы (3-гидрокси-3-метилглютарил-коэнзим А-редуктазы); секвестрантов; никотинилового спирта, никотиновой кислоты и ее соли, агонистов РАППа (PPARa); агонистов PPAR-альфа/гамма двойного действия, ингибиторов всасывания холестерина, ингибиторов ацил-Коэнзим А-холестерин ацилтрансферазы, антиоксидантов, агонистов РАППо, соединений для лечения ожирения, ингибитора илеального переносчика желчных кислот и противовоспалительных препаратов.
34. Соединение или его фармацевтически приемлемая соль по любому из пп.1-31 для применения в качестве лекарственного средства.
35. Применение соединения или его фармацевтически приемлемой соли по любому из пп.1-31 для изготовления лекарственного средства для лечения и профилактики инсулин-независимого сахарного диабета (Тип II) гипергликемии, ожирения, устойчивости к инсулину, нарушений обмена липидов, дислипидемии, гиперлипидемии, гипертриглицеридемии, гиперхолестеринемии, низких уровней ЛПВП, высоких уровней ЛПНП, атеросклероза, дефицита гормона роста, болезней, связанных с иммунными реакциями, ВИЧ инфекции, нейтропении, нейрональных заболеваний, метастазирования опухолей, доброкачественной гипертрофии предстательной железы, гингивита, гипертензии, остеопороза, заболеваний, связанных с подвижностью сперматозоидов, низкой толерантности к глюкозе, устойчивости к инсулину, ее последствий, рестеноза сосудов, синдрома раздраженного кишечника, воспалительных заболеваний кишечника, включая болезнь Крона и язвенный колит, других воспалительных заболеваний, панкреатита, абдоминального ожирения, нейродегенеративных заболеваний, тревожности, депрессии, ретинопатии, нефропатии, нейропатии, «синдрома X», гиперандрогенизма яичников (синдром поликистозных яичников), диабета Типа n или дефицита гормона роста.
36. Применение соединения по любому из пп.1-31 в качестве ингибитора ДПП-IV.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04005347.2 | 2004-03-05 | ||
EP04005347A EP1593671A1 (en) | 2004-03-05 | 2004-03-05 | DPP-IV inhibitors |
PCT/EP2005/002010 WO2005095343A1 (en) | 2004-03-05 | 2005-02-25 | Dpp-iv inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2006131597A true RU2006131597A (ru) | 2008-04-10 |
RU2345067C2 RU2345067C2 (ru) | 2009-01-27 |
Family
ID=34924473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2006131597/04A RU2345067C2 (ru) | 2004-03-05 | 2005-02-25 | Ингибиторы дпп-iv |
Country Status (11)
Country | Link |
---|---|
US (1) | US20070197522A1 (ru) |
EP (2) | EP1593671A1 (ru) |
JP (1) | JP2007526267A (ru) |
KR (1) | KR20070007816A (ru) |
CN (1) | CN1980892A (ru) |
AU (1) | AU2005229330B2 (ru) |
CA (1) | CA2558446A1 (ru) |
MX (1) | MXPA06010097A (ru) |
NO (1) | NO20064032L (ru) |
RU (1) | RU2345067C2 (ru) |
WO (1) | WO2005095343A1 (ru) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
PE20061156A1 (es) | 2004-12-23 | 2006-12-16 | Glaxo Group Ltd | Derivados de benzamida como agentes inhibidores del transportador de glicina |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
WO2007063928A1 (ja) * | 2005-11-30 | 2007-06-07 | Toray Industries, Inc. | 新規な非環状アミンカルボキシアミド誘導体及びその塩 |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
US20090156465A1 (en) * | 2005-12-30 | 2009-06-18 | Sattigeri Jitendra A | Derivatives of beta-amino acid as dipeptidyl peptidase-iv inhibitors |
US20100016374A1 (en) * | 2006-04-05 | 2010-01-21 | Steven Coulton | Compounds Which Inhibit the Glycine Transporter and Uses Thereof |
BRPI0709984A2 (pt) | 2006-04-12 | 2011-08-02 | Probiodrug Ag | inibidores de enzima |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
JP5323684B2 (ja) | 2006-05-04 | 2013-10-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 多形体 |
EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
WO2008130151A1 (en) * | 2007-04-19 | 2008-10-30 | Dong-A Pharm. Co., Ltd. | Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity |
PT2264009T (pt) | 2008-03-12 | 2019-04-29 | Ube Industries | Composto do ácido piridilaminoacético |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
CN102149407A (zh) | 2008-09-10 | 2011-08-10 | 贝林格尔.英格海姆国际有限公司 | 治疗糖尿病和相关病症的组合疗法 |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
CN107011345A (zh) | 2008-12-23 | 2017-08-04 | 勃林格殷格翰国际有限公司 | 有机化合物的盐形式 |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
PL2415763T3 (pl) | 2009-03-30 | 2016-05-31 | Ube Industries | Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry |
PL2475428T3 (pl) | 2009-09-11 | 2015-12-31 | Probiodrug Ag | Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej |
EP2504002B1 (en) | 2009-11-27 | 2019-10-09 | Boehringer Ingelheim International GmbH | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
MX341025B (es) | 2010-05-05 | 2016-08-04 | Boehringer Ingelheim Int Gmbh * | Terapia de combinacion. |
NZ603319A (en) | 2010-06-24 | 2015-04-24 | Boehringer Ingelheim Int | Diabetes therapy |
EP2418196A1 (en) * | 2010-07-29 | 2012-02-15 | IMTM GmbH | Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors |
DK3400944T3 (da) | 2010-11-08 | 2020-10-12 | Albireo Ab | Ibat-inhibitorer til behandling af leversygdomme |
US20120114588A1 (en) * | 2010-11-08 | 2012-05-10 | Albireo Ab | Ibat inhibitors for treatment of metabolic disorders and related conditions |
AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
PL2731947T3 (pl) | 2011-07-15 | 2019-07-31 | Boehringer Ingelheim International Gmbh | Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
JO3301B1 (ar) | 2013-04-26 | 2018-09-16 | Albireo Ab | تعديلات بلورية على إيلوبيكسيبات |
SG11201601682RA (en) | 2013-09-06 | 2016-04-28 | Aurigene Discovery Tech Ltd | 1,2,4-oxadiazole derivatives as immunomodulators |
ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
WO2015199147A1 (ja) | 2014-06-25 | 2015-12-30 | 味の素株式会社 | 固形製剤及びその着色防止又は着色低減方法 |
EP3012252A1 (en) | 2014-10-24 | 2016-04-27 | Ferring BV | Crystal modifications of elobixibat |
CN114213356A (zh) | 2015-03-10 | 2022-03-22 | 奥瑞基尼探索技术有限公司 | 作为免疫调节剂的1,2,4-噁二唑和噻二唑化合物 |
CN107427476A (zh) * | 2015-03-10 | 2017-12-01 | 奥瑞基尼探索技术有限公司 | 作为免疫调节剂的3‑取代的‑1,2,4‑噁二唑和噻二唑化合物 |
GB201511382D0 (en) | 2015-06-29 | 2015-08-12 | Imp Innovations Ltd | Novel compounds and their use in therapy |
US20190038611A1 (en) * | 2015-09-09 | 2019-02-07 | The Regents Of The University Of California | Novel CYP34A-Specific Inhibitors and Methods of Using Same |
US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
EP4233840A3 (en) | 2016-06-10 | 2023-10-18 | Boehringer Ingelheim International GmbH | Combinations of linagliptin and metformin |
CN111107902A (zh) * | 2017-03-14 | 2020-05-05 | 丹娜法伯癌症研究所 | Bax活化的用于诱导细胞死亡的小分子致敏 |
EP3664781A1 (en) | 2017-08-09 | 2020-06-17 | Albireo AB | Cholestyramine granules, oral cholestyramine formulations and use thereof |
PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
WO2019061324A1 (en) | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
JP2020536872A (ja) | 2017-10-11 | 2020-12-17 | オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited | 3−置換1,2,4−オキサジアゾールの結晶形態 |
EA202090746A1 (ru) | 2017-11-03 | 2020-08-17 | Ориджен Дискавери Текнолоджис Лимитед | Двойные ингибиторы путей tim-3 и pd-1 |
AU2018360389A1 (en) | 2017-11-06 | 2020-05-07 | Aurigene Oncology Limited | Conjoint therapies for immunomodulation |
US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
TW202015699A (zh) | 2018-06-05 | 2020-05-01 | 瑞典商艾爾比瑞歐公司 | 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽汁酸調節劑之用途 |
US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
SG11202012151XA (en) | 2018-06-20 | 2021-01-28 | Albireo Ab | Crystal modifications of odevixibat |
US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
EP4069361B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
KR20220109450A (ko) | 2019-12-04 | 2022-08-04 | 알비레오 에이비 | 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의 이의 용도 |
CA3158184A1 (en) | 2019-12-04 | 2021-08-10 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
EP4069359B1 (en) | 2019-12-04 | 2024-01-03 | Albireo AB | Benzothia(di)azepine compounds and their use as bile acid modulators |
CA3186857A1 (en) | 2020-08-03 | 2022-02-10 | Per-Goran Gillberg | Benzothia(di)azepine compounds and their use as bile acid modulators |
KR20230106651A (ko) | 2020-11-12 | 2023-07-13 | 알비레오 에이비 | 진행성 가족성 간내 담즙정체증(pfic)을 치료하기 위한 오데빅시바트 |
JP2024500309A (ja) | 2020-12-04 | 2024-01-09 | アルビレオ エービー | ベンゾチア(ジ)アゼピン化合物および胆汁酸モジュレータとしてのその使用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5455271A (en) * | 1992-06-18 | 1995-10-03 | The Scripps Research Institute | Tight-binding inhibitors of leukotriene A4 hydrolase |
DE19616486C5 (de) * | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
AU2002310465B2 (en) * | 2001-06-20 | 2006-06-15 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
EP1406872B1 (en) * | 2001-06-20 | 2007-12-19 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
AR043515A1 (es) * | 2003-03-19 | 2005-08-03 | Merck & Co Inc | Procedimiento para preparar derivados quirales beta aminoacidos mediante hidrogenacion asimetrica |
-
2004
- 2004-03-05 EP EP04005347A patent/EP1593671A1/en not_active Withdrawn
-
2005
- 2005-02-25 RU RU2006131597/04A patent/RU2345067C2/ru not_active IP Right Cessation
- 2005-02-25 MX MXPA06010097A patent/MXPA06010097A/es unknown
- 2005-02-25 JP JP2007501183A patent/JP2007526267A/ja not_active Withdrawn
- 2005-02-25 CN CNA2005800137836A patent/CN1980892A/zh active Pending
- 2005-02-25 CA CA002558446A patent/CA2558446A1/en not_active Abandoned
- 2005-02-25 WO PCT/EP2005/002010 patent/WO2005095343A1/en active Application Filing
- 2005-02-25 AU AU2005229330A patent/AU2005229330B2/en not_active Expired - Fee Related
- 2005-02-25 KR KR1020067020710A patent/KR20070007816A/ko active Application Filing
- 2005-02-25 US US10/591,108 patent/US20070197522A1/en not_active Abandoned
- 2005-02-25 EP EP05715551A patent/EP1758861A1/en not_active Withdrawn
-
2006
- 2006-09-07 NO NO20064032A patent/NO20064032L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MXPA06010097A (es) | 2007-06-15 |
CN1980892A (zh) | 2007-06-13 |
JP2007526267A (ja) | 2007-09-13 |
NO20064032L (no) | 2006-11-08 |
AU2005229330B2 (en) | 2008-12-18 |
AU2005229330A1 (en) | 2005-10-13 |
RU2345067C2 (ru) | 2009-01-27 |
WO2005095343A1 (en) | 2005-10-13 |
EP1758861A1 (en) | 2007-03-07 |
CA2558446A1 (en) | 2005-10-13 |
US20070197522A1 (en) | 2007-08-23 |
EP1593671A1 (en) | 2005-11-09 |
KR20070007816A (ko) | 2007-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2006131597A (ru) | Ингибиторы dпп-iv | |
RU2006140796A (ru) | Ингибиторы дпп-iv | |
RU2006119302A (ru) | Ингибиторы дпп-iv | |
RU2006140797A (ru) | Производные бензиламина 1-[(3r)-амино-4-(2-фторфенил)-бутил]-пирролидин-(2r)-карбоновой кислоты и родственные соединения в качестве ингибиторов дипептидил-пептидазы iv (дпп-iv) для терапии сахарного диабета второго типа | |
RU2006140795A (ru) | Ингибиторы дпп-iv | |
JP5420400B2 (ja) | Gタンパク質共役型レセプター作動剤 | |
RU2440997C2 (ru) | Производные циннамоил-пиперазина и их применение в качестве антагонистов par-1 | |
AR047669A1 (es) | Entidad seleccionada entre un compuesto de xantina y un derivado fisiologicamente funcional del mismo, su uso para la fabricacion de un medicamento, formulacion farmaceutica y combinacion de formulaciones que la comprenden y metodo para su preparacion | |
RU2006105717A (ru) | Производные пиперазина и их применение в качестве терапевтических агентов | |
RU2012121577A (ru) | Замещенные 3-фенилпропионовые кислоты и их применение | |
AR035320A1 (es) | Compuestos activadores de hppardelta, composicion farmaceutica, su uso en la preparacion de medicamentos, metodo para el tratamiento de enfermedades mediadas por hppardelta | |
CR7928A (es) | Medicamento para la profilaxis y el tratamiento de arteriosclerosis e hipertension | |
CY1106134T1 (el) | Συνθεση πepιεχουσα εναν ανταγωνιστη υποδοχεα αγγειοτενσινης ιι και ενα διουρητικο και η χρηση της για την θepαπεια της υπερτασης | |
RU2007140733A (ru) | Диариламинсодержащие соединения и композиции, и их применение в качестве модуляторов ядерных рецепторов стероидного гормона | |
RU2008106058A (ru) | Производные пиридазинона в качестве агонистов рецептора тиреоидного гормона | |
KR20040010748A (ko) | 당뇨병 치료제로서의 3-플루오로-피롤리딘 | |
RU97108980A (ru) | Производные бензимидазола, антигистаминовая фармацевтическая композиция и способ лечения аллергических заболеваний | |
JP2009190971A (ja) | 2−シアノピロリジン誘導体 | |
GT200000197A (es) | 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6- morfolin-4-il-4-o tolil-piridin-3-il)-isobutiramida. | |
PE20020910A1 (es) | p-TIENILBENCIL-AMIDAS COMO AGONISTAS DE RECEPTORES DE ANGIOTENSINA-(1-7), PROCEDIMIENTO PARA SU PREPARACION Y PREPARADOS FARMACEUTICOS QUE LOS CONTIENEN | |
RU2004111358A (ru) | Комбинированные агенты для лечения глаукомы | |
RU2006113550A (ru) | Циклогексильные производные, замещенные аминоалкиламидами | |
AR032009A1 (es) | Formulacion farmaceutica que contiene tienopirimidinas y antitromboticos, antagonistas de calcio, prostaglandinas o derivados de prostaglandina | |
RU2006109566A (ru) | Пиразолопиридины и их аналоги | |
RU2007125636A (ru) | Фенилпиперазины с комбинацией свойств сродства к d2 допаминовым рецепторам и центрам обратного захвата серотонина |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20090226 |